These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27431625)

  • 1. [How Long Should We Continue the Chemotherapy?-From the View Point of Health Economics].
    Koinuma N
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):809-18. PubMed ID: 27431625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Economic burden of cancer patients undergoing oral chemotherapy].
    Koinuma N
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1230-3. PubMed ID: 20647704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Problems with countermeasures for health insurance treatment in neurology].
    Ito M
    Rinsho Shinkeigaku; 2013; 53(11):923-5. PubMed ID: 24291834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future.
    Atieno OM; Opanga S; Martin A; Kurdi A; Godman B
    J Med Econ; 2018 Sep; 21(9):878-887. PubMed ID: 29860920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of out-of-pocket spending caps on financial burden of those with group health insurance.
    Riggs KR; Buttorff C; Alexander GC
    J Gen Intern Med; 2015 May; 30(5):683-8. PubMed ID: 25472507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of in-patient cancer chemotherapy at a tertiary care hospital.
    Wani MA; Tabish SA; Jan FA; Khan NA; Wafai ZA; Pandita KK
    J Cancer Res Ther; 2013; 9(3):397-401. PubMed ID: 24125973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forgotten public health impacts of cancer - an overview.
    Viegas S; Ladeira C; Costa-Veiga A; Perelman J; Gajski G
    Arh Hig Rada Toksikol; 2017 Dec; 68(4):287-297. PubMed ID: 29337686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How much is the life of a cancer patient worth? A pharmaco-economic perspective.
    Simoens S; Dooms M
    J Clin Pharm Ther; 2011 Jun; 36(3):249-56. PubMed ID: 21545607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic burden of anemia in cancer patients receiving chemotherapy.
    Lyman GH; Berndt ER; Kallich JD; Erder MH; Crown WH; Long SR; Lee H; Song X; Finkelstein SN
    Value Health; 2005; 8(2):149-56. PubMed ID: 15804323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The public funding of expensive cancer therapies: synthesizing the "3Es"--evidence, economics, and ethics.
    Kirby J; Somers E; Simpson C; McPhee J
    Organ Ethic; 2008; 4(2):97-108. PubMed ID: 18839752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.
    Schrag D; Hanger M
    J Clin Oncol; 2007 Jan; 25(2):233-7. PubMed ID: 17210946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacoeconomics and cost of cancer drugs].
    Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
    Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Going for Broke: A Longitudinal Study of Patient-Reported Financial Sacrifice in Cancer Care.
    Chino F; Peppercorn JM; Rushing C; Nicolla J; Kamal AH; Altomare I; Samsa G; Zafar SY
    J Oncol Pract; 2018 Sep; 14(9):e533-e546. PubMed ID: 30138052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Awareness about medical expenses and certifications of eligibility for limited health insurance payments for chemotherapy among clinicians at the Ehime Cancer Care Network Priority Hospitals (Ehime Cancer Kyoten Hospitals)].
    Yakushijin Y; Morita J; Yano T; Matsuhisa T; Kawazoe H; Kojima Y; Okada K; Kamei H; Hara M; Fujii M; Matsuno T; Tanimizu M; Shinkai T
    Gan To Kagaku Ryoho; 2014 May; 41(5):605-10. PubMed ID: 24917006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer.
    Davidoff AJ; Erten M; Shaffer T; Shoemaker JS; Zuckerman IH; Pandya N; Tai MH; Ke X; Stuart B
    Cancer; 2013 Mar; 119(6):1257-65. PubMed ID: 23225522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposal for the breakdown of increased cancer healthcare cost and its improvement.
    Koinuma N
    Jpn J Clin Oncol; 2013 Apr; 43(4):351-6. PubMed ID: 23423810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of cancer across the European Union: a population-based cost analysis.
    Luengo-Fernandez R; Leal J; Gray A; Sullivan R
    Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High cancer drug prices in the United States: reasons and proposed solutions.
    Kantarjian H; Steensma D; Rius Sanjuan J; Elshaug A; Light D
    J Oncol Pract; 2014 Jul; 10(4):e208-11. PubMed ID: 24803662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.